Peripheral neuropathy orchestrated by nonneural-specific lymphocytes

por Harvey, G.K., Gold, R., Toyka, K.V., Hartung, H.-P.
Publicado 1994

The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis

por Willison, A. G., Ruck, T., Lenz, G., Hartung, H. P., Meuth, S. G.
Publicado 2022

Correction to: The current standing of autologous haematopoietic stem cell transplantation for the treatment of multiple sclerosis

por Willison, A. G., Ruck, T., Lenz, G., Hartung, H. P., Meuth, S. G.
Publicado 2022

T cell receptor Vβ sequence analysis in target tissue suggests contribution of myelin basic protein autoreactivity to experimental allergic neuritis

por Giegerich, G., Weilbach, F., Gold, R., Toyka, K.V., Hartung, H.P.
Publicado 1994

Immune mechanisms in inflammatory polyneuropathy

por Toyka, Klaus V., Hartung, H.P., Heininger, K., Schäfer, B., Fierz, W.
Publicado 1987

Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis

por Schweitzer, F., Laurent, S., Fink, G. R., Barnett, Michael H., Hartung, H. P., Warnke, C.
Publicado 2020

Free caspase activity in CSF of patients with dementia

por Albrecht, P., Schmitz, M., Otto, M., Hemmer, B., Zerr, I., Hartung, H.-P., Methner, Axel
Publicado 2009

Recommendations for a Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS)

por Langdon, DW, Amato, MP, Boringa, J, Brochet, B, Foley, F, Fredrikson, S, Hämäläinen, P, Hartung, H-P, Krupp, L, Penner, IK, Reder, AT, Benedict, RHB
Publicado 2012

A Case of Relapsing-Remitting Neuroborreliosis? Challenges in the Differential Diagnosis of Recurrent Myelitis

por Albrecht, P., Henke, N., Lehmann, H.C., Macht, S., Hefter, H., Goebels, N., Mackenzie, C., Rupprecht, T.A., Fingerle, V., Hartung, H.P., Methner, A.
Publicado 2012

Dual roles of the adenosine A2a receptor in autoimmune neuroinflammation

por Ingwersen, J., Wingerath, B., Graf, J., Lepka, K., Hofrichter, M., Schröter, F., Wedekind, F., Bauer, A., Schrader, J., Hartung, H.-P., Prozorovski, T., Aktas, O.
Publicado 2016

Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT

por Edan, G, Kappos, L, Montalbán, X, Polman, C H, Freedman, M S, Hartung, H-P, Miller, D, Barkhof, F, Herrmann, J, Lanius, V, Stemper, B, Pohl, C, Sandbrink, R, Pleimes, D
Publicado 2014

Predictive nature of IgM anti-α-glucose serum biomarker for relapse activity and EDSS progression in CIS patients: a BENEFIT study analysis

por Freedman, MS, Metzig, C, Kappos, L, Polman, CH, Edan, G, Hartung, H-P, Miller, DH, Montalban, X, Yarden, J, Spector, L, Fire, E, Dotan, N, Schwenke, S, Lanius, V, Sandbrink, R, Pohl, C
Publicado 2012

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis

por Hartung, H-P, Berger, T, Bermel, RA, Brochet, B, Carroll, WM, Holmøy, T, Karabudak, R, Killestein, J, Nos, C, Patti, F, Ross, A Perrin, Vanopdenbosch, L, Vollmer, T, Buffels, R, Garas, M, Kadner, K, Manfrini, M, Wang, Q, Freedman, MS
Publicado 2020